KCIA
ALZN icon

Kingsbury Capital Investment Advisors’s Alzamend Neuro ALZN Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19
Closed -$22K – 78
2022
Q2 		$22K Buy
19
+10
+111% +$13K 0.03% 92
2022
Q1 		$14K Buy
+9
New +$16.9K 0.02% 97

Other funds holding ALZN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return

Kingsbury Capital Investment Advisors's ALZN Position: Q3 2022 in Review

Kingsbury Capital Investment Advisors sold out of Alzamend Neuro (ALZN) in Q3 2022, closing a stake of 19 shares — an estimated $22K sold.

Kingsbury Capital Investment Advisors first reported a position in ALZN in Q1 2022 and held it in 2 quarters. The position peaked at $22K in Q2 2022. 15 funds tracked by Wall St. Rank hold ALZN as of Q3 2022.

  • Kingsbury Capital Investment Advisors reported no remaining Alzamend Neuro position as of Q3 2022 after selling out during the quarter.
  • Kingsbury Capital Investment Advisors sold 19 Alzamend Neuro shares in Q3 2022, an estimated $22K.
  • Kingsbury Capital Investment Advisors first reported a position in Alzamend Neuro in Q1 2022 and held it in 2 quarters.
  • Kingsbury Capital Investment Advisors's Alzamend Neuro position peaked at $22K in Q2 2022.
  • 15 funds tracked by Wall St. Rank held Alzamend Neuro as of Q3 2022.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.